- Joined
- Dec 1, 2006
- Messages
- 31
- Reaction score
- 5
The last posts I could find on these agents were over 4 years old.
Interested whether anyone here has experience with any of these drugs yet. The current indications are still fairly restrictive [SSTI, telavancin apparently got HAP as well] but it sounds like they are actively pursuing data to support osteo. The advantages are obvious -- particularly for oritavancin with its lower cost, one time dosing (can you tell we've had a rep visit?). Cost is still a major consideration, ~$2600 for the "less-expensive" oritavancin, and it seems unclear whether it will even be paid for. However for certain outpatient situations it may make sense. I like dosing, monitoring for vancomycin. . .but this new class may end up taking over eventually. Very interesting MOA(s), PK, and spectrum. Any hospitals actually using any of these agents?
OK, honestly I don't care. Just wanted to get a little more 'pharmacy' on the pharmacy board.
Interested whether anyone here has experience with any of these drugs yet. The current indications are still fairly restrictive [SSTI, telavancin apparently got HAP as well] but it sounds like they are actively pursuing data to support osteo. The advantages are obvious -- particularly for oritavancin with its lower cost, one time dosing (can you tell we've had a rep visit?). Cost is still a major consideration, ~$2600 for the "less-expensive" oritavancin, and it seems unclear whether it will even be paid for. However for certain outpatient situations it may make sense. I like dosing, monitoring for vancomycin. . .but this new class may end up taking over eventually. Very interesting MOA(s), PK, and spectrum. Any hospitals actually using any of these agents?
OK, honestly I don't care. Just wanted to get a little more 'pharmacy' on the pharmacy board.